Key Highlights

  • Compass Pathways (NASDAQ:CMPS) recorded a USD 9.8 million net loss for the third quarter, cushioned by a USD 40.8 million non-cash Warrant gain; cash stood at USD 444.0 million on September 30, 2026.
  • Third-quarter sales at QuidelOrtho (NASDAQ:QDEL) totaled USD 618.9 million, an 11.6% decline, while the 2026 adjusted EPS outlook tightened to USD 0.65 to USD 0.70, versus a prior USD 0.65 to USD 0.90.
  • The Enovis (NYSE:ENOV) figures are due Thursday, November 5, 2026, and none had been published beforehand.
  • The FDA shifted the Capricor Therapeutics (NASDAQ:CAPR) action date to November 22, 2026, a move that followed a 3 to 9 committee tally on July 29, 2026.

Compass Pathways (NASDAQ:CMPS): Warrant Accounting Carries Most of the Narrowed Quarterly Loss

Compass Pathways (NASDAQ:CMPS) posted its third-quarter 2026 figures on November 3, 2026. The loss came to USD 9.8 million, equal to USD 0.07 per basic share or USD 0.31 per diluted share, yet a non-cash gain of USD 40.8 million tied to warrant liabilities accounted for most of the improvement. Adding Research and Development to general and administrative outlays gives USD 56.5 million, a sum worked out here from two reported lines. Based in London, the Business is advancing COMP360, a psilocybin treatment aimed at depression that resists standard therapy. Its rolling new drug application is close to completion, with the last piece due within a fortnight, and a launch is aimed at the opening six months of 2027, conditional on regulatory approval. So far, no acceptance date or action date has been announced. Cash and equivalents rose to USD 444.0 million from USD 149.6 million at year-end 2025, a level management expects to carry operations into 2028. Liabilities for Debt climbed to USD 51.0 million, compared with USD 31.6 million earlier. Market data from a public feed puts the one-year EPS change at 109.03%, with a share price near USD 8.36 (down 2.68%), yet neither figure reconciles with the filing. Because the company is loss-making, per-share swings reflect warrant Revaluation rather than operating results. Market Capitalization has not been verified. Risks include a regulatory setback, cost pressure from launch activity and potential dilution.

QuidelOrtho (NASDAQ:QDEL): Sales Slide and a Narrowed Adjusted EPS Range

QuidelOrtho (NASDAQ:QDEL) filed results for the period ending September 27, 2026 on November 3, 2026. Sales came in at USD 618.9 million, a decline of 11.6% against USD 699.9 million. Point of Care Revenue dropped 27.3% to USD 119.6 million, which the company tied to a milder respiratory season. Labs sales declined 5.5% to USD 353.2 million. The GAAP net loss amounted to USD 53.8 million, or USD 0.78 a share, versus USD 733.0 million, or USD 10.78, in the prior-year period. The excerpt of the release does not explain that prior-year loss, so no cause is assumed here. Adjusted diluted EPS dropped roughly 61% to USD 0.31 from USD 0.80, a figure from simple arithmetic. A published data feed shows a 122.63% one-year EPS change and a price near USD 14.14, up 0.36%, though the snapshot is undated and the numbers do not match the filing. The GAAP loss shrank mainly because the earlier loss was so much bigger, a base effect rather than an operating gain. Market capitalization has not been verified. The 2026 adjusted EPS outlook now spans USD 0.65 to USD 0.70, while annual revenue guidance was lowered to a USD 2.52 billion to USD 2.54 billion band. Debt stood near USD 2.94 billion against USD 166.4 million in cash, and nine-month free Cash Flow came in at negative USD 202.8 million. Management expects savings above USD 80 million during 2027.

Enovis (NYSE:ENOV): Pre-Results Stage With a 14.86% Price Jump on the Screen

Medical technology firm Enovis (NYSE:ENOV) has its third-quarter 2026 release slated for Thursday, November 5, 2026, accompanied by a call for investors and a webcast. As of November 4, 2026, the company had not published any 2026 revenue, profit or outlook numbers, which makes this a preview rather than an account of results. A data feed quotes the shares at USD 24.00, a 14.86% rise, alongside a 30.94% one-year EPS change. Neither the snapshot time nor any catalyst is shown, and none of these numbers has been checked. A calendar page put the stock 38.5% lower since its last Earnings release, a figure that is also unverified. For comparison, coverage of the 2025 third-quarter call reported adjusted EPS of USD 0.75, up 3%, with revenue up 9% as reported and 7% on an organic basis. The same coverage described a USD 548 million non-cash Goodwill write-down during 2025, linked to a sustained fall in the share price and market value. Such a write-down can distort a GAAP comparison, making the growth rate look dramatic when the base is negative. It is unclear whether the screen used GAAP or adjusted figures. Possible downsides include a weak outlook, more impairments if the shares remain depressed, and a pullback from the recent gain. Nothing in this piece forecasts results or the market response.

Capricor Therapeutics (NASDAQ:CAPR): Deramiocel Decision Slips to Late November

Clinical-stage biotech Capricor Therapeutics (NASDAQ:CAPR) is developing deramiocel, a cell-based treatment for Duchenne muscular dystrophy. An announcement on August 24, 2026 explained that a filing containing 24-month open-label extension data was classified as a major amendment, which moved the decision date off August 22 and onto November 22, 2026. On July 29, 2026, a panel split 3 to 9 on whether substantial effectiveness for cardiomyopathy had been demonstrated, a result with no binding force. The company has proposed a more focused label built around upper limb function, the main endpoint that HOPE-3 reached with a p-value of 0.029. Holdings of cash and marketable securities totaled roughly USD 237.9 million at June 30, 2026, against about USD 318.1 million at the 2025 year-end. The second-quarter loss amounted to roughly USD 40.7 million, equal to USD 0.70 per share, versus USD 25.9 million in the comparison period, and no revenue was booked. A screen showed a one-year EPS change of 48.91% and a price near USD 8.27, up 0.36%. These figures are unconfirmed, and a widening loss does not square with EPS growth. Biotech stocks can swing hard on regulatory news either way, and a dispute with a distribution partner is set to go to arbitration this autumn.

Where Things Stand

Accounting explains most of this, not operating progress. A non-cash warrant gain carried most of the quarterly narrowing at Compass Pathways (NASDAQ:CMPS), while launch preparations remain ahead. At QuidelOrtho (NASDAQ:QDEL), GAAP losses narrowed against a huge prior-year figure, and adjusted EPS slid. Enovis (NYSE:ENOV) reports on November 5, 2026. Capricor Therapeutics (NASDAQ:CAPR) has an FDA action date set for November 22, 2026. Screened EPS readings remain unconfirmed and are shaped by base effects, since a large prior-year loss or Impairment can make any move look outsized.